[89Zr]-Df-Trastuzumab

N/A

Report date: 2025/11/21 17:16:15

Base Information

Drug Name[89Zr]-Df-Trastuzumab

Drug Alias NameN/A

ClassificationDiagnostic agent (In vivo)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agent +[5]

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursBreast NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Alabama At Birmingham

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Alabama At Birmingham

Inactive CompaniesWashington University School Of Medicine

Active IndicationsBreast Neoplasms

Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A